Theravance Biopharma TBPH Europe — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Theravance Biopharma’s 10-K, filed March 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Theravance Biopharma's europe — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Theravance Biopharma's europe — revenue?
- Theravance Biopharma (TBPH) reported europe — revenue of $8.13M in Q4 2025.
- What is the long-term trend for Theravance Biopharma's europe — revenue?
- Over 3 years (2021 to 2025), Theravance Biopharma's europe — revenue has grown at a 849.2% compound annual growth rate (CAGR), from $38K to $32.5M.
- What does europe — revenue mean?
- This metric represents the total gross revenue generated from product sales, licensing, or service agreements within the European geographic market, excluding any assessed taxes. It serves as a key indicator of the company's commercial penetration and market adoption of its organ-selective medicines in this specific region. Tracking this revenue stream helps investors evaluate the success of international commercialization strategies and the growth trajectory of the company's therapeutic portfolio outside of its primary markets.